270 FMT C-terminal domain-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 1 | 8.7 | 0.12× | q = 4.9e-4 | |
| Nucleosides, nucleotides, and analogues | 15 | 4.9 | 3.06× | not tested | |
| Organic acids and derivatives | 6 | 2.8 | 2.19× | not tested | |
| Organoheterocyclic compounds | 5 | 2.7 | 1.83× | not tested | |
| Organic oxygen compounds | 2 | 3.5 | 0.57× | not tested | |
| Homogeneous non-metal compounds | 1 | 3.8 | 0.26× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03434 | MPO | 3-(N-morpholino)propanesulfonic acid | 14 |
| DB03256 | FON | (6R)-Folinic acid | 13 |
| DB03103 | TYD | Thymidine-5'- Diphosphate | 11 |
| DB01992 | COA | Coenzyme A | 8 |
| DB02031 | THG | (6S)-5,6,7,8-tetrahydrofolic acid | 4 |
| DB00116 | — | — | 2 |
| DB03435 | UDP | Uridine-5'-Diphosphate | 2 |
| DB03685 | U5P | Uridine monophosphate | 2 |
| DB03751 | DAU | 2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose | 2 |
| DB04315 | GDP | Guanosine-5'-Diphosphate | 2 |
| DB00158 | FOL | Folic acid | 1 |
| DB02078 | PG5 | Triglyme | 1 |
| DB02857 | GMP | Guanosine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAmetal | SODIUM ION | 17 |
| MPO | 3[N-MORPHOLINO]PROPANE SULFONIC ACID | 14 |
| TYD | THYMIDINE-5'-DIPHOSPHATE | 13 |
| 0FX | dTDP-4-amino-4,6-dideoxyglucose | 12 |
| T3F | (3R,4S,5R,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl][hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate | 9 |
| COA | COENZYME A | 8 |
| T3Q | [(3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl][hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] hydrogen phosphate | 8 |
| FON | N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid | 4 |
| G3N | (2R,3R,4S,5S)-5-amino-3,4-dihydroxytetrahydro-2H-pyran-2-yl [(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl dihydrogen diphosphate | 4 |
| THG | (6S)-5,6,7,8-TETRAHYDROFOLATE | 3 |
| 1YA | N-{4-[{[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}(formyl)amino]benzoyl}-L-glutamic acid | 2 |
| CL | CHLORIDE ION | 2 |
| DAU | 2'DEOXY-THYMIDINE-5'-DIPHOSPHO-ALPHA-D-GLUCOSE | 2 |
| EP1 | 3-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]PROPANE-1-SULFONIC ACID | 2 |
| FNF | (2R,3R,4S,5R,6R)-4-(formylamino)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl [(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl dihydrogen diphosphate (non-preferred name) | 2 |
| GDP | GUANOSINE-5'-DIPHOSPHATE | 2 |
| U5P | URIDINE-5'-MONOPHOSPHATE | 2 |
| UDP | URIDINE-5'-DIPHOSPHATE | 2 |
| 1YF | [(2R,3R,4S,5S,6R)-4-formamido-6-methyl-3,5-bis(oxidanyl)oxan-2-yl] [[(2R,3S,5R)-5-[5-methyl-2,4-bis(oxidanylidene)pyrimidin-1-yl]-3-oxidanyl-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] hydrogen phosphate | 1 |
| 1YJ | N-[4-({[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid | 1 |